Journal of the American Society of Nephrology, Vol 7, 582-593, Copyright © 1996 by American Society of Nephrology

REGULAR ARTICLES

Phosphodiesterase inhibitors correct resistance to natriuretic peptides in rats with Heymann Nephritis

JP Valentin, WZ Ying, LA Sechi, KT Ling, C Qiu, WG Couser and MH Humphreys
Division of Nephrology, San Francisco General Hospital, University of California 94143, USA.

Experimental nephrotic syndrome is characterized by abnormal sodium metabolism, reflected in a blunted natriuretic response both to volume expansion and to infused atrial natriuretic peptide (ANP). The studies presented here examined the relationships among plasma ANP concentration and urinary sodium (VNaV) and cyclic GMP excretion (UcGMPV) in vivo, and the responsiveness of isolated glomeruil and inner medullary collecting duct (IMCD) cells to ANP and urodilatin (renal natriuretic peptide; RNP) in vitro in rats with Heymann nephritis, an immunologically mediated model of nephrotic syndrome. Nine to 14 days after Ip injection of anti-Fx1A antiserum, rats were proteinuric and had a blunted natriuretic response to intravenous infusion of isotonic saline (2% body weight, given over 5 min). Thirty min after the onset of the infusion, plasma ANP concentration was increased to the same extent in both normal and nephritic rats, compared with their respective hydropenic controls. Despite this increase, UcGMPV was significantly less in nephritic rats after the saline infusion. Accumulation of cGMP by isolated glomeruil and IMCD cells from nephritic rats after incubation with ANP and RNP was also significantly reduced, compared with normal rats. This difference was not related to differences in either density or affinity of renal ANP receptors, but was abolished when accumulation of cGMP was measured in the presence of 10(-3) M isobutylmethylxanthine or Zaprinast, two different inhibitors of cyclic nucleotide phosphodiesterases (PDE). Infusion of Zaprinast into one renal artery in nephritic rats normalized both the natriuretic response to volume expansion and the increase in UcGMPV from the infused, but not the contralateral, kidney. Furthermore, cGMP-PDE activity was increased in IMCD cell homogenates from nephritic compared with normal rats (388 +/- 32 versus 198 +/- 93 pmol/min per mg protein, P < 0.03). These results indicate that blunted volume expansion natriuresis accompanied by cellular resistance to ANP in vitro occurs in an immunologic model of renal injury. The resistance is not related to an alteration in ANP release or binding to its renal receptors, but is suppressed by PDE inhibitors and is associated with increased renal cGMP. PDE activity, thus suggesting that enhanced cGMP- PDE activity may account for resistance to the natriuretic actions of ANP observed in vivo. This defect may represent the intrinsic sodium transport abnormality linked to sodium retention in nephrotic syndrome.

This article has been cited by other articles:

				J. Cheng and J. P. Grande Cyclic Nucleotide Phosphodiesterase (PDE) Inhibitors: Novel Therapeutic Agents for Progressive Renal Disease Experimental Biology and Medicine, January 1, 2007; 232(1): 38 - 51. [Abstract] [Full Text] [PDF]

				H. H. Chen, B. K. Huntley, J. A. Schirger, A. Cataliotti, and J. C. Burnett Jr Maximizing the Renal Cyclic 3'-5'-Guanosine Monophosphate System with Type V Phosphodiesterase Inhibition and Exogenous Natriuretic Peptide: A Novel Strategy to Improve Renal Function in Experimental Overt Heart Failure J. Am. Soc. Nephrol., October 1, 2006; 17(10): 2742 - 2747. [Abstract] [Full Text] [PDF]

				B. Sampaio-Maia, M. Moreira-Rodrigues, P. Serrao, and M. Pestana Blunted renal dopaminergic system activity in puromycin aminonucleoside-induced nephrotic syndrome Nephrol. Dial. Transplant., February 1, 2006; 21(2): 314 - 323. [Abstract] [Full Text] [PDF]

				R. Bouley, N. Pastor-Soler, O. Cohen, M. McLaughlin, S. Breton, and D. Brown Stimulation of AQP2 membrane insertion in renal epithelial cells in vitro and in vivo by the cGMP phosphodiesterase inhibitor sildenafil citrate (Viagra) Am J Physiol Renal Physiol, June 1, 2005; 288(6): F1103 - F1112. [Abstract] [Full Text] [PDF]

				H. C. Thiesson, B. L. Jensen, B. Jespersen, O. B. Schaffalitzky de Muckadell, C. Bistrup, S. Walter, P. D. Ottosen, A. Veje, and O. Skott Inhibition of cGMP-specific phosphodiesterase type 5 reduces sodium excretion and arterial blood pressure in patients with NaCl retention and ascites Am J Physiol Renal Physiol, May 1, 2005; 288(5): F1044 - F1052. [Abstract] [Full Text] [PDF]

				M. Kikuchi, S. Fujimoto, H. Fukae, H. Kinoshita, T. Kita, M. Nakazato, and T. Eto Role of Uroguanylin, a Peptide with Natriuretic Activity, in Rats with Experimental Nephrotic Syndrome J. Am. Soc. Nephrol., February 1, 2005; 16(2): 392 - 397. [Abstract] [Full Text] [PDF]

				X.-P. Ni, M. Safai, R. Rishi, C. Baylis, and M. H. Humphreys Increased Activity of cGMP-Specific Phosphodiesterase (PDE5) Contributes to Resistance to Atrial Natriuretic Peptide Natriuresis in the Pregnant Rat J. Am. Soc. Nephrol., May 1, 2004; 15(5): 1254 - 1260. [Abstract] [Full Text] [PDF]

				L. L. Hamm and V. Batuman Edema in the Nephrotic Syndrome: New Aspect of an Old Enigma J. Am. Soc. Nephrol., December 1, 2003; 14(12): 3288 - 3289. [Full Text] [PDF]

				J. Kotera, K. Fujishige, and K. Omori Immunohistochemical Localization of cGMP-binding cGMP-specific Phosphodiesterase (PDE5) in Rat Tissues J. Histochem. Cytochem., May 1, 2000; 48(5): 685 - 694. [Abstract] [Full Text]

				J.-P. Valentin, W.-Z. Ying, W. G. Couser, and M. H. Humphreys Extrarenal resistance to atrial natriuretic peptide in rats with experimental nephrotic syndrome Am J Physiol Renal Physiol, March 1, 1998; 274(3): F556 - F563. [Abstract] [Full Text] [PDF]

Copyright © 2008 by the American Society of Nephrology. Online ISSN: 1533-3450 Print ISSN: 1046-6673